Cargando…

The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru

BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cárdenas, María Kathia, Mirelman, Andrew J., Galvin, Cooper J., Lazo-Porras, María, Pinto, Miguel, Miranda, J. Jaime, Gilman, Robert H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623251/
https://www.ncbi.nlm.nih.gov/pubmed/26503154
http://dx.doi.org/10.1186/s12913-015-1141-4
_version_ 1782397659554775040
author Cárdenas, María Kathia
Mirelman, Andrew J.
Galvin, Cooper J.
Lazo-Porras, María
Pinto, Miguel
Miranda, J. Jaime
Gilman, Robert H.
author_facet Cárdenas, María Kathia
Mirelman, Andrew J.
Galvin, Cooper J.
Lazo-Porras, María
Pinto, Miguel
Miranda, J. Jaime
Gilman, Robert H.
author_sort Cárdenas, María Kathia
collection PubMed
description BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic costs. METHODS: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline), standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty was tested with a one-way sensitivity analysis. RESULTS: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths. CONCLUSION: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention strategies such as incorporating temperature monitoring may also be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-1141-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4623251
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46232512015-10-28 The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru Cárdenas, María Kathia Mirelman, Andrew J. Galvin, Cooper J. Lazo-Porras, María Pinto, Miguel Miranda, J. Jaime Gilman, Robert H. BMC Health Serv Res Research Article BACKGROUND: Diabetes mellitus is a public health challenge worldwide, and roughly 25 % of patients with diabetes in developing countries will develop at least one foot ulcer during their lifetime. The gravest outcome of an ulcerated foot is amputation, leading to premature death and larger economic costs. METHODS: This study aimed to estimate the economic costs of diabetic foot in high-risk patients in Peru in 2012 and to model the cost-effectiveness of a year-long preventive strategy for foot ulceration including: sub-optimal care (baseline), standard care as recommended by the International Diabetes Federation, and standard care plus daily self-monitoring of foot temperature. A decision tree model using a population prevalence-based approach was used to calculate the costs and the incremental cost-effectiveness ratio (ICER). Outcome measures were deaths and major amputations, uncertainty was tested with a one-way sensitivity analysis. RESULTS: The direct costs for prevention and management with sub-optimal care for high-risk diabetics is around US$74.5 million dollars in a single year, which decreases to US$71.8 million for standard care and increases to US$96.8 million for standard care plus temperature monitoring. The implementation of a standard care strategy would avert 791 deaths and is cost-saving in comparison to sub-optimal care. For standard care plus temperature monitoring compared to sub-optimal care the ICER rises to US$16,124 per death averted and averts 1,385 deaths. CONCLUSION: Diabetic foot complications are highly costly and largely preventable in Peru. The implementation of a standard care strategy would lead to net savings and avert deaths over a one-year period. More intensive prevention strategies such as incorporating temperature monitoring may also be cost-effective. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12913-015-1141-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-26 /pmc/articles/PMC4623251/ /pubmed/26503154 http://dx.doi.org/10.1186/s12913-015-1141-4 Text en © Cárdenas et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Cárdenas, María Kathia
Mirelman, Andrew J.
Galvin, Cooper J.
Lazo-Porras, María
Pinto, Miguel
Miranda, J. Jaime
Gilman, Robert H.
The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title_full The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title_fullStr The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title_full_unstemmed The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title_short The cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in Peru
title_sort cost of illness attributable to diabetic foot and cost-effectiveness of secondary prevention in peru
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623251/
https://www.ncbi.nlm.nih.gov/pubmed/26503154
http://dx.doi.org/10.1186/s12913-015-1141-4
work_keys_str_mv AT cardenasmariakathia thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT mirelmanandrewj thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT galvincooperj thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT lazoporrasmaria thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT pintomiguel thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT mirandajjaime thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT gilmanroberth thecostofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT cardenasmariakathia costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT mirelmanandrewj costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT galvincooperj costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT lazoporrasmaria costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT pintomiguel costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT mirandajjaime costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu
AT gilmanroberth costofillnessattributabletodiabeticfootandcosteffectivenessofsecondarypreventioninperu